Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum

Nadine Rouphael,Allison Beck,Amy E Kirby,Pengbo Liu,Muktha S Natrajan,Lilin Lai,Varun Phadke,Juton Winston,Vanessa Raabe,Matthew H Collins,Tigisty Girmay,Alicarmen Alvarez,Nour Beydoun,Vinit Karmali,Joanne Altieri-Rivera,Lisa C Lindesmith,Evan J Anderson,Yuke Wang,Jill El-Khorazaty,Carey Petrie,Ralph S Baric,Shahida Baqar,Christine L Moe,Mark J Mulligan

DOI: https://doi.org/10.1093/infdis/jiac045

2022-11-11

Abstract:Background: Genogroup II noroviruses are the most common cause of acute infectious gastroenteritis. We evaluated the use of a new GII.2 inoculum in a human challenge. Methods: Forty-four healthy adults (36 secretor-positive and 8 secretor-negative for histo-blood group antigens) were challenged with ascending doses of a new safety-tested Snow Mountain virus (SMV) GII.2 norovirus inoculum (1.2 × 104 to 1.2 × 107 genome equivalent copies [GEC]; n = 38) or placebo (n = 6). Illness was defined as diarrhea and/or vomiting postchallenge in subjects with evidence of infection (defined as GII.2 norovirus RNA detection in stool and/or anti-SMV immunoglobulin G [IgG] seroconversion). Results: The highest dose was associated with SMV infection in 90%, and illness in 70% of subjects with 10 of 12 secretor-positive (83%) and 4 of 8 secretor-negative (50%) becoming ill. There was no association between prechallenge anti-SMV serum IgG concentration, carbohydrate-binding blockade antibody, or salivary immunoglobulin A and infection. The median infectious dose (ID50) was 5.1 × 105 GEC. Conclusions: High rates of infection and illness were observed in both secretor-positive and secretor-negative subjects in this challenge study. However, a high dose will be required to achieve the target of 75% illness to make this an efficient model for evaluating potential norovirus vaccines and therapeutics. Clinical trials registration: NCT02473224.